CA-CLICKHOUSE
ClickHouse, Inc., the company behind the world’s fastest and most popular real-time analytical database, is thrilled to announce the acquisition of PeerDB, a leading provider of change data capture (CDC) solutions for Postgres databases. This strategic acquisition underscores ClickHouse’s commitment to delivering unparalleled real-time analytics and data integration capabilities to its customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240730221289/en/
ClickHouse acquires PeerDB to boost real-time analytics with Postgres CDC integration (Graphic: Business Wire)
PeerDB’s technology significantly reduces the time it takes to connect data in transactional databases like Postgres with analytical databases like ClickHouse, boosting developer productivity and time-to-value when building real-time data driven applications. With PeerDB CDC technology integrated into ClickHouse Cloud, users will benefit from seamless, real-time data replication from Postgres databases to ClickHouse.
“We are excited to welcome PeerDB into ClickHouse,” said Aaron Katz, CEO of ClickHouse, Inc. “This acquisition aligns with our mission to empower our customers with the most advanced and efficient data analytics solutions. By integrating PeerDB’s CDC technology, we are empowering Postgres developers to move even faster when building real-time data driven applications. Now, all they have to do is configure a mirror between their existing Postgres databases and ClickHouse, and the data is available for lightning-fast analytical queries.”
Sai Krishna Srirampur, CEO of PeerDB, expressed his enthusiasm for what the future holds, stating, “We are thrilled to join forces with ClickHouse. This acquisition is a natural evolution for us at PeerDB, as we already share many joint enthusiastic users with ClickHouse. Postgres is becoming the de facto operational database, while ClickHouse is the fastest analytical database on the planet. Both originate from the same open-source ethos. This acquisition bridges the gap between Postgres and ClickHouse, enabling businesses to seamlessly move their operational data for real-time analytics.”
Javier Erro Garcia, Cloud Architecture Manager at Vueling Airlines, shared excitement about the upcoming integration: “As a user of both ClickHouse Cloud and PeerDB, I am thrilled about this acquisition. We already reduced our Postgres to ClickHouse snapshot times from 10+ hours down to 15 minutes with PeerDB. Combining ClickHouse’s powerful analytics natively with PeerDB’s real-time data capture capabilities will greatly simplify our data processing workflows. This integration will enable us to build analytical applications faster, giving us a competitive edge in the market.”
The combined expertise of ClickHouse and PeerDB will pave the way for the development of new features and capabilities aimed at meeting the evolving needs of data-driven enterprises. Customers can look forward to deeper integration between PeerDB Cloud and ClickHouse Cloud and support for additional CDC data sources. The ClickHouse technical blog post introducing the acquisition provides more detail.
About ClickHouse
ClickHouse is a fast, open-source, columnar OLAP database management system. It allows users to generate analytics using SQL queries in real-time. Designed to analyze large volumes of data, ClickHouse is used by industry leaders around the globe for its unmatched performance, scalability, and reliability.
About PeerDB
PeerDB is a leading provider of change data capture (CDC) solutions for Postgres databases. Their technology enables real-time data replication and synchronization, helping businesses keep their data up-to-date and accessible for analytics and decision-making processes.
PeerDB was founded by Kaushik Iska and Sai Srirampur in mid 2023 and has since grown to become a leading Postgres data replication company in the market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240730221289/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom